Keywords: antisoma, begins, ph, ii, as1411, aml, trial

Antisoma begins Ph II AS1411 AML trial

Article | 13 August 2007

Print This

UK-based cancer drug developer Antisoma has initiated a Phase II trial of its developmental oncology agent AS1411 in the treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in